Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients

A clinical practice guideline for adult patients with unresectable or metastatic/recurrent gastrointestinal stromal tumours that have become resistant or intolerant to imatinib mesylate. The guideline examines the efficacy of sunitinib malate as an alternative, and reviews what dosing regimens could be observed. Outcomes of interest include partial response, but no difference in quality of life.